Released Mar 13, 2026, after the close
10-K filed Mar 13, 2026, 72 days after period end · 0001493152-26-010102
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$1.50M-$1.50M derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$2,095,000N/M
Operating Cash Flowderived-$1,148,000N/M
Free Cash Flowderived-$1,163,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | $1.00K | — | — |
| Net Income | -$1.50M | -$5.76M | -$6.15M | -$4.49M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR